Given that overexpression of Sp7 in osteoblasts using a transgenic approach resulted in osteopenia with suppression of osteoblast differentiation [16], an appropriate dosage of Sp7 may be required for the proper execution of the osteoblast program in adults. The gene discussed is SP7; the disease is Osteopenia.